IUC26693-91 Cholesterol homeostasis and immune-inflammatory profiles in patients with mRCC receiving immunotherapy

Abstract Background Cholesterol metabolism may modulate antitumor immunity, influencing response to immune-checkpoint inhibitors (ICIs). We evaluated cholesterol transport-related biomarkers, KIM-1, and inflammatory mediators in metastatic renal cell carcinoma (mRCC) patients treated with first-line ICI-based regimens, to characterize the immune–metabolic profiles. Methods LINCHOLM is a prospective, multicentre, observational study. Patients with mRCC receiving ICI-based combinations underwent blood collection at baseline, week 6 and progression. ABCA1- and ABCG1-mediated cholesterol efflux (CE), lipid fractions, and inflammatory mediators were assessed. Primary objective was to investigate associations between baseline cholesterol transporters and inflammatory mediators, and progression-free survival (PFS). Results 33 patients were included, 84.8% had ECOG PS 0-1. Across worsening IMDC risk groups Apo-A1, total cholesterol, HDL and LDL decreased (all p≤0.03), whereas KIM-1, IL-6 and Apo-E increased (all p≤0.02). High ABCG1-mediated CE correlated with higher levels of ApoE and IL-1β (all p≤0.04). High KIM-1 was associated with poorer ECOG PS, synchronous metastatic disease, and higher NLR, IL-4, IL-6, and IL-10 (all p≤0.04), Figure 1. High baseline ABCG1-mediated CE, KIM-1, ApoE, NLR, and inflammatory cytokines (IL-4, IL-6, IFN-γ, IL-10, IL-1β, IL-2, and TNF-α) correlated with shorter PFS, Table 1. Only ABCG1 remained independently associated with worse PFS at multivariable analysis (HR 10.61, 95%CI 2.35–47.97; p = 0.002), although estimates were limited by small sample size. Conclusions ABCG1-mediated CE may serve as a prognostic biomarker in mRCC patients receiving first-line ICI-based therapies. The interplay among cholesterol metabolism, KIM-1, and inflammatory mediators suggests a biological profile influencing outcomes and warrants further validation. Acknowledgements Project funded by the European Union - NextGenerationEU, Mission 4 Component 1, Unique Project Code (CUP): D53D23013940006

Authors

Institutions

Publication Details

Journal
The Oncologist
Published
2026-08-21
DOI
https://doi.org/10.1093/oncolo/oyag286.027
Primary Topic
Cancer, Lipids, and Metabolism
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

IUC26693-91 Cholesterol homeostasis and immune-inflammatory profiles in patients with mRCC receiving immunotherapy

S Buti, G Mazzaschi, G Leali, M Pluchino et al.
The Oncologist
Cancer, Lipids, and Metabolism
article

IUC26693-91 Cholesterol homeostasis and immune-inflammatory profiles in patients with mRCC receiving immunotherapy

S Buti, G Mazzaschi, G Leali, M Pluchino, P Tuttobene, M Tiseo, M Maffezzoli, F Pecci, E Favari, M Di Maio
article en

Abstract

Abstract Background Cholesterol metabolism may modulate antitumor immunity, influencing response to immune-checkpoint inhibitors (ICIs). We evaluated cholesterol transport-related biomarkers, KIM-1, and inflammatory mediators in metastatic renal cell carcinoma (mRCC) patients treated with first-line ICI-based regimens, to characterize the immune–metabolic profiles. Methods LINCHOLM is a prospective, multicentre, observational study. Patients with mRCC receiving ICI-based combinations underwent blood collection at baseline, week 6 and progression. ABCA1- and ABCG1-mediated cholesterol efflux (CE), lipid fractions, and inflammatory mediators were assessed. Primary objective was to investigate associations between baseline cholesterol transporters and inflammatory mediators, and progression-free survival (PFS). Results 33 patients were included, 84.8% had ECOG PS 0-1. Across worsening IMDC risk groups Apo-A1, total cholesterol, HDL and LDL decreased (all p≤0.03), whereas KIM-1, IL-6 and Apo-E increased (all p≤0.02). High ABCG1-mediated CE correlated with higher levels of ApoE and IL-1β (all p≤0.04). High KIM-1 was associated with poorer ECOG PS, synchronous metastatic disease, and higher NLR, IL-4, IL-6, and IL-10 (all p≤0.04), Figure 1. High baseline ABCG1-mediated CE, KIM-1, ApoE, NLR, and inflammatory cytokines (IL-4, IL-6, IFN-γ, IL-10, IL-1β, IL-2, and TNF-α) correlated with shorter PFS, Table 1. Only ABCG1 remained independently associated with worse PFS at multivariable analysis (HR 10.61, 95%CI 2.35–47.97; p = 0.002), although estimates were limited by small sample size. Conclusions ABCG1-mediated CE may serve as a prognostic biomarker in mRCC patients receiving first-line ICI-based therapies. The interplay among cholesterol metabolism, KIM-1, and inflammatory mediators suggests a biological profile influencing outcomes and warrants further validation. Acknowledgements Project funded by the European Union - NextGenerationEU, Mission 4 Component 1, Unique Project Code (CUP): D53D23013940006

The OncologistVol. 31(Supplement_2)
University of Parma (IT), Azienda Ospedaliera Citta' della Salute e della Scienza di Torino (IT), University Hospitals Parma Medical Center (US)
No poverty
Openalex Percentile: Top 13%
Cancer, Lipids, and Metabolism
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.